Last reviewed · How we verify
A Study of 18F-MFBG Imaging for the Tumor Burden Evaluation or Diagnostic Performance in Pheochromocytoma, Paraganglioma and Neuroblastoma.
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).
Details
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | RECRUITING |
| Enrolment | 150 |
| Start date | 2021-09-01 |
| Completion | 2026-12 |
Conditions
- Neuroendocrine Tumor
- Neuroblastoma
- Pheochromocytoma
- Paraganglioma
Interventions
- 18F-MFBG
- 68Ga-Dotatate
Primary outcomes
- The evaluation of diagnostic performance of 18F-MFBG PET in different regions in metastatic neural crest tumor. — through study completion, an average of 1 year
Patients with histologically confirmed metastatic neural crest tumor will be prospectively recruited in this study. They will receive 18F-MFBG PETand 123I-MIBG SPECT. Rate of detected lesions (visual) in bone, lymph node and liver will be compared.
Countries
China